{"fetched":"2026-09-09","congress":{"id":"asco","label":"ASCO Annual Meeting","year":2026,"journal":"Journal of Clinical Oncology","window":{"from":"2026-05-10","to":"2026-06-20"},"source":"https://api.crossref.org/"},"total":7365,"considered":7222,"matched":1530,"items":[{"doi":"10.1200/jco.2026.44.16_suppl.7007","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7007","title":"Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["polatuzumab-vedotin","mosunetuzumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","oxaliplatin","rituximab"],"trials":["sunmo"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4016","title":"A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","trastuzumab","gemcitabine","cisplatin","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["her2"],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6535","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6535","title":"Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cyclophosphamide","tafasitamab","doxorubicin","vincristine","platinum-etoposide","rituximab","etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4642","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4642","title":"TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["datopotamab-deruxtecan","enfortumab-vedotin","pembrolizumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4160","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4160","title":"Durvalumab or pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for advanced cholangiocarcinoma: A meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","durvalumab","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4070","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4070","title":"Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","oxaliplatin","durvalumab","docetaxel","flot"],"trials":["matterhorn"],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6013","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6013","title":"Induction chemotherapy with nab-paclitaxel and cisplatin versus docetaxel, cisplatin, and fluorouracil followed by chemoradiotherapy in patients with stage III–IVA nasopharyngeal carcinoma: An open-label, noninferiority, randomized, controlled, phase 3 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","fluorouracil","docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6125","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6125","title":"Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","tislelizumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps7099","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7099","title":"Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["acalabrutinib","zanubrutinib","sonrotoclax","venetoclax"],"trials":["celestial-tncll","celestial"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16177","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16177","title":"A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","cadonilimab","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4265","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4265","title":"A prospective single-arm study of irinotecan liposome II combined with adebrelimab, gemcitabine, and nab-paclitaxel for conversion therapy in locally advanced pancreatic cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","irinotecan"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4111","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4111","title":"Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","ramucirumab","trastuzumab","paclitaxel"],"trials":["destiny-gastric04"],"targets":["her2"],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4024","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4024","title":"An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","nivolumab","relatlimab-nivolumab","capox"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8541","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8541","title":"Association of gut microbiota and peri-initiation proton pump inhibitor/antibiotic exposure with outcomes of atezolizumab-bevacizumab-carboplatin-paclitaxel regimen in patients with advanced non-squamous NSCLC: Prospective phase II study (K-TAIL-201).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab","carboplatin","paclitaxel"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4112","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4112","title":"Bortezomib plus gemcitabine-cisplatin versus gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancers: A randomized phase II clinical trial with exploratory analysis of PTEN status.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","bortezomib","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7081","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7081","title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["brentuximab-vedotin","cyclophosphamide","doxorubicin","platinum-etoposide","etoposide"],"trials":[],"targets":["cd30"],"cancers":["peripheral-t-cell-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2630","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2630","title":"Clinical efficacy of tislelizumab in combination with gemcitabine and nab-paclitaxel and chemoresistance analysis in borderline resectable pancreatic cancer: A prospective pilot study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","tislelizumab","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9513","title":"Combination of vemurafenib with cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["vemurafenib","cobimetinib","ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["braf"],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16190","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16190","title":"Combined therapy using gemcitabine and cisplatin chemotherapy, lenvatinib, and adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","lenvatinib","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16232","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16232","title":"Comparative effectiveness and healthcare utilization of atezolizumab plus bevacizumab versus durvalumab plus tremelimumab in older patients with advanced hepatocellular carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tremelimumab","atezolizumab","bevacizumab-glioma","bevacizumab","durvalumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16385","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16385","title":"Comparative effectiveness of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients aged ≧ 75 years with metastatic pancreatic cancer: A multinational real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","folfirinox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4163","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4163","title":"Comparative outcomes of first-line atezolizumab plus bevacizumab (A+B) and durvalumab plus tremelimumab (D+T) in hepatocellular carcinoma (HCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tremelimumab","atezolizumab","bevacizumab-glioma","bevacizumab","durvalumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16221","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16221","title":"Comparative survival and long-term gastrointestinal outcomes of ipilimumab/nivolumab vs durvalumab/tremelimumab in unresectable hepatocellular carcinoma: A propensity-matched real-world analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tremelimumab","ipilimumab","durvalumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4583","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4583","title":"Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","carboplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3584","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3584","title":"Correlative analysis of ctDNA in CheckMate-9X8 study of frontline treatment with mFOLFOX6, bevacizumab with or without nivolumab in metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","nivolumab","relatlimab-nivolumab","folfox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16367","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16367","title":"Efficacy and safety by tumor location in the phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":["panova-3"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4245","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4245","title":"Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A randomized controlled phase 3 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["disitamab-vedotin","pembrolizumab","tislelizumab","trastuzumab","capox"],"trials":[],"targets":["her2"],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16382","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16382","title":"Efficacy profile of nanoliposomal irinotecan + fluorouracil and leucovorin (nal-IRI+5-FU/LV) in gemcitabine-refractory metastatic pancreatic adenocarcinoma in elderly North American patients: A real-word experience.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","irinotecan"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4152","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4152","title":"Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","lenvatinib","cisplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3684","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3684","title":"Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","fruquintinib","tislelizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4510","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4510","title":"Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enfortumab-vedotin","pembrolizumab","gemcitabine-cisplatin","cisplatin"],"trials":["ev-303"],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4002","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4002","title":"IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab","lenvatinib","sorafenib"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16170","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16170","title":"Ivonescimab plus gemcitabine/cisplatin and stereotactic body radiotherapy as first-line treatment for advanced biliary tract cancer: A single-arm, open-label, phase II exploratory study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","ivonescimab","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16465","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16465","title":"Liposomal irinotecan combined with oxaliplatin, 5-fluorouracil/leucovorin with or without camrelizumab as preoperative chemotherapy for borderline resectable pancreatic cancer: Preliminary results of a single-center phase II exploratory study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","fluorouracil","oxaliplatin","irinotecan"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20128","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20128","title":"Liposomal irinotecan plus cisplatin/carboplatin as second-line therapy for platinum-sensitive relapsed extensive-stage small cell lung cancer: Interim results of a phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","irinotecan","gemcitabine-cisplatin","cisplatin","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16519","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16519","title":"Metastatic renal cell carcinoma treated with pembrolizumab–lenvatinib versus nivolumab–cabozantinib: A real-world analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","cabozantinib","lenvatinib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4613","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4613","title":"Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enfortumab-vedotin","pembrolizumab","gemcitabine-cisplatin","cisplatin"],"trials":["ev-303"],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4614","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4614","title":"Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enfortumab-vedotin","pembrolizumab","gemcitabine-cisplatin","cisplatin"],"trials":["ev-304"],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6014","title":"Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","ivonescimab","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":["pd1","vegf"],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.620","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.620","title":"Neoadjuvant mitomycin C plus carboplatin followed by paclitaxel vs. standard doxorubicin–cyclophosphamide followed by paclitaxel–carboplatin in BRCA1/2-associated breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cyclophosphamide","doxorubicin","carboplatin","mitomycin","paclitaxel"],"trials":[],"targets":["brca"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6127","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6127","title":"OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","fluorouracil","amivantamab","carboplatin","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16436","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16436","title":"Overall survival and treatment-related outcomes with FOLFIRINOX compared with gemcitabine/nab-paclitaxel in metastatic pancreatic cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","folfirinox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5503","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5503","title":"Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","relacorilant","platinum-etoposide"],"trials":["rosella"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e17595","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e17595","title":"Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in recurrent platinum-resistant ovarian cancer: A real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cyclophosphamide","pembrolizumab","bevacizumab-glioma","bevacizumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4200","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4200","title":"Phase Ib/II clinical study of adebrelimab combined with decitabine, nab-paclitaxel, and gemcitabine as first-line (IL) treatment for metastatic pancreatic cancer (mPC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","decitabine-cedazuridine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4515","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4515","title":"Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14059","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14059","title":"Phase II study of liposomal irinotecan in combination with cisplatin and bevacizumab for high-grade recurrent glioma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","irinotecan","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3512","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3512","title":"Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","panitumumab","bevacizumab","folfiri","folfox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16159","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16159","title":"Real-world comparison of atezolizumab/bevacizumab vs durvalumab/tremelimumab in decompensated hepatocellular carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tremelimumab","atezolizumab","bevacizumab-glioma","bevacizumab","durvalumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23442","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23442","title":"Real-world overall survival with platinum–pemetrexed chemotherapy versus ipilimumab–nivolumab in peritoneal mesothelioma: A propensity-matched multicenter analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pemetrexed","ipilimumab","nivolumab","relatlimab-nivolumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["mesothelioma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4193","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4193","title":"Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","folfirinox","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10030","title":"Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","methotrexate","doxorubicin","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4263","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4263","title":"TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","relacorilant","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1042","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1042","title":"Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","tucatinib"],"trials":["her2climb-05","her2climb"],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16468","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16468","title":"Updated results of a single-arm phase II clinical trial of gemcitabine, cisplatin, and nab-paclitaxel as neoadjuvant therapy for pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1021","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1021","title":"A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","pertuzumab"],"trials":["destiny-breast09"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8594","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8594","title":"A phase 2 study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for patients with metastatic or recurrent non–small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","ramucirumab","docetaxel","platinum-etoposide"],"trials":[],"targets":["pdl1","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16410","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16410","title":"A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4129","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4129","title":"A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","capecitabine-temozolomide","oxaliplatin","capox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11599","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11599","title":"A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab, for advanced soft tissue sarcomas (NCT05876715).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8559","title":"A phase II study of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non–small cell lung cancer: TORG2241(UBE-Q).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","pembrolizumab","carboplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1163","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1163","title":"A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","bevacizumab-glioma","bevacizumab","paclitaxel"],"trials":[],"targets":["pdl1"],"cancers":["tnbc"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4252","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4252","title":"A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3682","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3682","title":"A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","ivonescimab","folfox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7569","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7569","title":"Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lenalidomide","daratumumab","bortezomib"],"trials":["cepheus"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3600","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3600","title":"An early on-treatment \"coordinated inflammatory niche\" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","cadonilimab","folfirinox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3681","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3681","title":"Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","encorafenib","cetuximab"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4528","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4528","title":"Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","sunitinib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4530","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4530","title":"Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","sunitinib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7513","title":"Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lenalidomide","daratumumab","bortezomib"],"trials":["cepheus"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3566","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3566","title":"Efficacy and circulating protein biomarkers of second-line aflibercept plus FOLFIRI according to prior bevacizumab or cetuximab treatment in advanced colorectal cancer (KCSG CO21-21).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","cetuximab","folfiri"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5526","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5526","title":"Efficacy and safety of cadonilimab (CD) in combination with disitamab vedotin (RC48) or nab-paclitaxel (NP) in the treatment of recurrent or metastatic cervical cancer (r/mCC): A prospective, double-cohort, multicenter, open-label, phase II clinical study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["disitamab-vedotin","gemcitabine-nab-paclitaxel","paclitaxel","cadonilimab"],"trials":[],"targets":[],"cancers":["cervical"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1009","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1009","title":"Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: The HELEN-Trio 011 randomized clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","carboplatin","docetaxel"],"trials":[],"targets":[],"cancers":["tnbc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5034","title":"Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["disitamab-vedotin","toripalimab","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16391","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16391","title":"Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens in locally advanced pancreatic carcinoma: A systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","folfirinox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16405","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16405","title":"Efficacy and safety outcomes of biweekly compared with standard triweekly gemcitabine/nab-paclitaxel in advanced pancreatic cancer: A systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18030","title":"Empegfilgrastim for primary febrile neutropenia prophylaxis during induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4118","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4118","title":"Envafolimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","oxaliplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6131","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6131","title":"ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","paclitaxel","cetuximab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20115","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20115","title":"Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","atezolizumab","durvalumab","tarlatamab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps10058","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps10058","title":"Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","irinotecan","naxitamab"],"trials":[],"targets":[],"cancers":["neuroblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8560","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8560","title":"FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non–small cell lung cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8058","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8058","title":"Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb EGFR -mutated non–small cell lung cancer: A single-arm, single-center, open-label phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","pemetrexed","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8649","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8649","title":"Five-year outcomes of osimertinib-based treatment in a phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin plus pemetrexed as a first-line treatment for advanced non-squamous non–small-cell lung cancer harboring EGFR mutation (JCOG1404/WJOG8214L).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["osimertinib","pemetrexed","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":["egfr"],"cancers":["nsclc","sclc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5644","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5644","title":"FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mirvetuximab-soravtansine","bevacizumab-glioma","bevacizumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15539","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15539","title":"Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","fruquintinib","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16070","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16070","title":"Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","fruquintinib","camrelizumab","paclitaxel"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3576","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3576","title":"Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","ivonescimab","oxaliplatin","folfox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16387","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16387","title":"Longitudinal on-treatment plasma microRNA profiling for identification of biomarker signatures associated with gemcitabine/nab-paclitaxel therapy in pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8669","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8669","title":"Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ramucirumab","cemiplimab","docetaxel","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7507","title":"MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pomalidomide","carfilzomib","teclistamab","bortezomib"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8099","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8099","title":"Multicenter phase II trial of atezolizumab plus carboplatin and etoposide for extensive-stage small cell lung cancer older patients who underwent geriatric assessment (OLCSG2002 EPAS Trial).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","carboplatin","platinum-etoposide","etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":["geriatric-assessment"]}},{"doi":"10.1200/jco.2026.44.16_suppl.9571","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9571","title":"Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage III acral melanoma: Updated CAP 03-NEO trial results and external control comparison.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","camrelizumab-rivoceranib","capecitabine-temozolomide","camrelizumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18063","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18063","title":"Neoadjuvant serplulimab combined with cisplatin plus 5-fluorouracil in locally advanced head and neck squamous cell carcinoma: A phase II single-arm trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","serplulimab","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e12658","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12658","title":"Neoadjuvant toripalimab combined with inetetamab, pertuzumab, and nab-paclitaxel in HER2-positive breast cancer (TORCH): A phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","toripalimab","pertuzumab"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3532","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3532","title":"Nivolumab + ipilimumab (NIVO + IPI) vs NIVO in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC): CheckMate 8HW subgroup analyses including treatment-free status and outcomes in long-term survivors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":["checkmate-8hw"],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21507","title":"Nivolumab plus temozolomide (Nivo/Tem) vs. temozolomide monotherapy in refractory melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9538","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9538","title":"Novel adaptive versus continuous dosing of encorafenib and binimetinib in combination with nivolumab in advanced BRAF V600E mutant melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["binimetinib","encorafenib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["braf"],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5634","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5634","title":"NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with BRCA1/2 -mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","platinum-etoposide","olaparib"],"trials":[],"targets":["brca"],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1079","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1079","title":"Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fulvestrant","palbociclib","inavolisib"],"trials":["inavo120"],"targets":["pik3ca","her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1019","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1019","title":"Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab","paclitaxel"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4084","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4084","title":"Paclitaxel/cisplatin (TP) vs cisplatin/5-fluorouracil (PF) neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC): A randomized trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","paclitaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7566","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7566","title":"PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","pomalidomide","bortezomib"],"trials":["dreamm-8"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18085","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18085","title":"Phase 1 study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in locally advanced squaous cell carcinoma of the head and neck (LA SCCHN).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cemiplimab","docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10039","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10039","title":"Phase I study of the LiViT regimen (liposomal irinotecan, vincristine, and temozolomide) in pediatric patients with relapsed/refractory solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","vincristine","irinotecan"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15578","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15578","title":"Phase II study of bevacizumab plus trifluridine/tipiracil and irinotecan as second-line therapy for RAS wild-type metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab","irinotecan"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4260","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4260","title":"Phase II study of NC410 and FOLFIRINOX in combination with nivolumab with or without ipilimumab in patients with treatment-naive metastatic pancreatic cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["folfirinox","ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4213","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4213","title":"Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4202","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4202","title":"Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4203","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4203","title":"QL1706 combined with nab-paclitaxel and gemcitabine as first-line treatment for locally advanced or metastatic pancreatic adenocarcinoma: A prospective, multicenter, single-arm phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18551","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18551","title":"Real-world comparative outcomes of intensive induction with 7+3 plus midostaurin versus azacitidine, venetoclax, and gilteritinib in FLT3-mutated acute myeloid leukemia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gilteritinib","azacitidine","midostaurin","venetoclax"],"trials":[],"targets":["flt3"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5640","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5640","title":"RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","carboplatin","paclitaxel"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e17604","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e17604","title":"Safety and efficacy of relacorilant and nab-paclitaxel in platinum resistant ovarian cancer: A GRADE assessed systematic review and meta-analysis of randomized controlled trials.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","relacorilant","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.516","title":"Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab-emtansine","trastuzumab"],"trials":["destiny-breast05"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11574","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11574","title":"Sintilimab (PD-1 antibody) plus gemcitabine and docetaxel (GT) as first-line or later-line therapy in patients with advanced epithelioid sarcoma: A prospective, multicenter, single-arm, phase II clinical study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","docetaxel"],"trials":[],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4192","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4192","title":"Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":["cldn18-2","cd47"],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7046","title":"Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zanubrutinib","bendamustine","rituximab"],"trials":["sequoia"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3504","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3504","title":"SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF V600E metastatic colorectal cancer (mCRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["encorafenib","cetuximab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4030","title":"Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","oxaliplatin","paclitaxel","irinotecan"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15554","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15554","title":"Tislelizumab combined with bevacizumab and trifluridine/tipiracil as third-line or later therapy for metastatic colorectal cancer (mCRC) : A real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","tislelizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16224","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16224","title":"Tolerance of gemcitabine–oxaliplatin (GEMOX) in advanced and metastatic gallbladder cancer: A real-world, single-center retrospective study from north India.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","oxaliplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5554","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5554","title":"Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)–expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","bevacizumab-glioma","bevacizumab","trastuzumab"],"trials":[],"targets":["her2"],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11562","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11562","title":"Triplet combination of anlotinib plus nab-paclitaxel and gemcitabine (AG) as a first-line strategy for advanced primary cardiac angiosarcoma: A high-volume center experience.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5636","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5636","title":"TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-tirumotecan","bevacizumab-glioma","bevacizumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5628","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5628","title":"TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-tirumotecan","pembrolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":["pdl1"],"cancers":["cervical"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1145","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1145","title":"TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","platinum-etoposide","tucatinib","etoposide"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5502","title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","carboplatin","paclitaxel"],"trials":["nrg-gy018-keynote-868"],"targets":[],"cancers":["endometrial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4136","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4136","title":"Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4564","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4564","title":"Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L cisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update on Duravelo-1 B7.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zelenectide-pevedotin","pembrolizumab","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6503","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6503","title":"A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1 -mutated acute myeloid leukemia (AML).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azacitidine","ivosidenib","venetoclax"],"trials":[],"targets":["idh"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3567","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3567","title":"A multicenter phase II trial of encorafenib, binimetinib, and cetuximab for early relapsed stage II/III BRAF V600E -mutated colorectal cancer: TRESBIEN trial (OGSG 2101).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["binimetinib","encorafenib","cetuximab"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9612","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9612","title":"A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6129","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6129","title":"A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ficerafusp-alfa","pembrolizumab"],"trials":["fortifi-hn01"],"targets":["pdl1"],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2700","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2700","title":"A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["mds"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11586","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11586","title":"A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6603","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6603","title":"A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1 -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["olutasidenib","azacitidine","venetoclax"],"trials":[],"targets":["idh"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2576","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2576","title":"A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["endometrial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6600","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6600","title":"A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azacitidine","venetoclax","revumenib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2663","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2663","title":"A phase I study of pomalidomide and nivolumab (Pom/Nivo) in patients with virus-associated malignancies with and without HIV.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pomalidomide","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4123","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4123","title":"A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","lenvatinib"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9501","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9501","title":"A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1041","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1041","title":"A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-emtansine","trastuzumab","ribociclib"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18067","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18067","title":"A phase II trial of a novel induction regimen: Polymeric micellar paclitaxel plus cisplatin for locally advanced head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11559","title":"A phase II, multi-cohort study with pemetrexed plus cisplatin combination in patients with relapsed or refractory advanced soft tissue sarcoma: Leiomyosarcoma cohort (ALBATROSS-SARC-LMS01).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pemetrexed","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20171","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20171","title":"A phase II, single-arm trial of adebrelimab plus nab-paclitaxel and carboplatin as first-line therapy for advanced thymic carcinoma: Interim efficacy and safety results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","carboplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6048","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6048","title":"A prospective, single-arm, phase II exploratory clinical study on the efficacy and safety of neoadjuvant adebrelimab combined with cisplatin and docetaxel in patients with clinical stage IVB oral squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21514","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21514","title":"A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8677","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8677","title":"A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with EGFR -mutant, MET -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ramucirumab","osimertinib","capmatinib-tepotinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8554","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8554","title":"A randomized phase III study of pembrolizumab versus pembrolizumab with carboplatin plus pemetrexed for locally advanced or metastatic nonsquamous non–small cell lung cancer with PD-L1 TPS ≥ 50%: LAPLACE-50.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","carboplatin","pemetrexed"],"trials":[],"targets":["pdl1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9597","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9597","title":"A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["vusolimogene-oderparepvec","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["ctla4","pd1"],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9598","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9598","title":"A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["uveal-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16563","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16563","title":"Adjuvant nivolumab compared with platinum-based chemotherapy in bladder cancer: A real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4254","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4254","title":"Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab"],"trials":["clear"],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2103","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2103","title":"Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH -mutated newly diagnosed grade 3 astrocytoma (VORTEX).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","vorasidenib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1013","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1013","title":"ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","pembrolizumab"],"trials":["ascent-04"],"targets":["pdl1"],"cancers":["tnbc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5001","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5001","title":"Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["decipher-prostate","enzalutamide","docetaxel"],"trials":[],"targets":[],"cancers":[],"technologies":["androgen-deprivation"]}},{"doi":"10.1200/jco.2026.44.16_suppl.2644","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2644","title":"Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","trastuzumab","pertuzumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18110","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18110","title":"Audiometric outcomes for intravenous sodium thiosulfate for cisplatin-induced ototoxicity prevention in adults with head and neck cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sodium-thiosulfate","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3559","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3559","title":"BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["binimetinib","encorafenib","cetuximab"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7512","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7512","title":"Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","lenalidomide","daratumumab"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23270","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23270","title":"Belzutifan plus lenvatinib versus cabozantinib in post–PD-(L)1 renal cell carcinoma (RCC): Health-related quality-of-life (HRQoL) outcomes in the phase 3 LITESPARK-011 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","lenvatinib","belzutifan"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5607","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5607","title":"Bevacizumab rechallenge in platinum-resistant ovarian cancer: Evidence from a propensity score–matched analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4538","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4538","title":"Body composition and quality of life (QOL) with lenvatinib + everolimus (len + eve) versus cabozantinib (cabo) in metastatic clear cell renal cell carcinoma (ccRCC) after PD-1 inhibitor progression: Results from the randomized phase II LenCabo trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","everolimus","lenvatinib"],"trials":[],"targets":["pd1"],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8606","title":"Brigatinib after lorlatinib and/or chemotherapy following first-line alectinib in ALK-rearranged NSCLC: Cohort B of the WJOG11919L/ABRAID study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lorlatinib","brigatinib","alectinib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.12080","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.12080","title":"BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","oxaliplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9516","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9516","title":"Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cadonilimab","ivonescimab","axitinib"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18016","title":"Camrelizumab combined with capecitabine as maintenance therapy for metastatic nasopharyngeal carcinoma: A phase II single-arm clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","capecitabine-temozolomide","camrelizumab"],"trials":[],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11513","title":"Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","doxorubicin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1064","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1064","title":"CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with PIK3CA -mutant circulating DNA following CDK4/6 inhibition.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","fulvestrant","alpelisib"],"trials":[],"targets":["pik3ca","cdk4-6"],"cancers":[],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.6004","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6004","title":"Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["nasopharyngeal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4257","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4257","title":"CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","folfox"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4042","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4042","title":"Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","zanidatamab"],"trials":["herizon-gea-01"],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4525","title":"CheckMate-901: Association of tumor and peripheral biomarker profiles with durable disease control in metastatic urothelial carcinoma treated with nivolumab plus ipilimumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15583","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15583","title":"Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","regorafenib","serplulimab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7536","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7536","title":"Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ciltacabtagene-autoleucel","lenalidomide"],"trials":["cartitude-4"],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3511","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3511","title":"Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["panitumumab","sotorasib"],"trials":["codebreak-300"],"targets":["kras"],"cancers":["colorectal"],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.1138","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1138","title":"Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","cobimetinib","eribulin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23415","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23415","title":"Clinical outcomes and safety of trifluridine–tipiracil with or without bevacizumab in metastatic colorectal cancer: A real-world study from Saudi Arabia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4244","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4244","title":"Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma: The phase ll IKF-090/AIO ZANGEA trial with translational analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","zanidatamab","folfox"],"trials":[],"targets":["pdl1","her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5083","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5083","title":"Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["darolutamide","relugolix"],"trials":["clear"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21513","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21513","title":"Comparative effectiveness of pembrolizumab and nivolumab as first-line treatment for advanced/unresectable or metastatic melanoma: A propensity-score adjusted analysis from a US national health system.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21587","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21587","title":"Comparative real-world safety of nivolumab versus pembrolizumab in malignant melanoma: A propensity-matched cohort study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16272","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16272","title":"Conversion therapy with PD-1/PD-L1 inhibitors plus gemcitabine-based chemotherapy for initially unresectable locally advanced gallbladder cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":["pdl1","pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2008","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2008","title":"Correlation of ten-year survival with cell-free DNA methylation of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8621","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8621","title":"Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of EGFR ‐mutated advanced non–small cell lung cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["amivantamab","osimertinib","lazertinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23169","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23169","title":"Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR -mutant NSCLC in the US and China.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["amivantamab","osimertinib","lazertinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6044","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6044","title":"Cytokine dynamics in a phase II trial of metronomic carboplatin/paclitaxel combined with cemiplimab in recurrent/metastatic head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","cemiplimab","paclitaxel"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3593","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3593","title":"Data from a real-world study: Association of CDCP1 expression level with survival outcomes in mCRC patients treated with bevacizumab or cetuximab plus chemotherapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","cetuximab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.609","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.609","title":"Delayed serplulimab combined with nab-paclitaxel and epirubicin in high-risk, early HR+/HER2− breast cancer (HELEN-B 018): A multicenter, single-arm, phase 2 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","serplulimab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7503","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7503","title":"DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","lenalidomide","bortezomib"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7565","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7565","title":"Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","pomalidomide"],"trials":["dreamm-8"],"targets":["bcma"],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14572","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14572","title":"Durvalumab plus platinum-etoposide in extensive-stage extrapulmonary small cell carcinoma (ES-EPSCC): Second safety assessment of the DURVASCC trial (GOIRC-01-2021).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["durvalumab","platinum-etoposide","etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3606","title":"Dynamics of circulating monomeric C-reactive protein (mCRP) to predict outcomes with first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["oxaliplatin","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.606","title":"Early results of neoadjuvant therapy with pyrotinib, subcutaneous trastuzumab, and capecitabine for HER2-positive early breast cancer from a prospective, single-arm, multicenter trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","trastuzumab","pyrotinib"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10052","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10052","title":"Effects of delayed sodium thiosulfate on cisplatin-induced ototoxicity in pediatric and adolescent patients with cancer: Results from the Japanese Children’s Cancer Group STS-J01 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sodium-thiosulfate","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11525","title":"Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ifosfamide","platinum-etoposide","etoposide"],"trials":[],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.599","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.599","title":"Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","paclitaxel"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15602","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15602","title":"Efficacy and safety of cadonilimab plus chemotherapy and bevacizumab as second-line treatment in patients with RAS -mutant metastatic colorectal cancer: Preliminary findings of a multi-center, single-arm study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","cadonilimab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3537","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3537","title":"Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in RAS wild-type metastatic colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["regorafenib","irinotecan","cetuximab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7514","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7514","title":"Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["daratumumab","bortezomib","iberdomide"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11526","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11526","title":"Efficacy and safety of perioperative anlotinib combined with cisplatin and doxorubicin in treatment-naive stage IIB classic osteosarcoma of the extremity: Updated results from the ALTER-S002 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["doxorubicin","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["osteosarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1005","title":"Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","tucatinib"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16115","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16115","title":"Efficacy of adjuvant S-1 vs capecitabine plus oxaliplatin (XELOX) chemotherapy among gastric cancer patients after D2 gastrectomy: A systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","oxaliplatin","capox"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13040","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13040","title":"Efficacy of datopotamab deruxtecan after trastuzumab deruxtecan in metastatic hormone receptor–positive HER2-negative breast cancer: A real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":["breast-hr-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4531","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4531","title":"Efficacy of fruquintinib (F) plus sintilimab (S) versus axitinib (A) or everolimus (E) by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma (RCC): A subgroup analysis of the FRUSICA-2 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","everolimus","axitinib"],"trials":[],"targets":["pdl1"],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4533","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4533","title":"Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","everolimus","axitinib"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1047","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1047","title":"Efficacy, safety, and immunogenicity of pertuzumab biosimilar versus reference pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer: A randomized, double-blind, multicenter, parallel group, phase III clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","docetaxel"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4507","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4507","title":"Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enfortumab-vedotin","pembrolizumab"],"trials":["ev-302"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1085","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1085","title":"Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2− metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["palbociclib","abemaciclib","ribociclib"],"trials":[],"targets":["her2","cdk4-6"],"cancers":[],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.4223","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4223","title":"Exosomal miRNA signatures as predictors of response to neoadjuvant FOLFIRINOX and GEM/nab-paclitaxel in resectable pancreatic cancer: The PRECEPT study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","folfirinox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3043","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3043","title":"Extracellular matrix-derived liquid biopsy for predicting response in patients with biliary tract cancer treated with nivolumab with or without ipilimumab combined with stereotactic body radiotherapy: Insights from the CheckPAC trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":["liquid-biopsy"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20667","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20667","title":"Factors influencing the selection of CheckMate-9LA (nivolumab, ipilimumab, and chemotherapy) regimen in AGA-negative advanced NSCLC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4504","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4504","title":"Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fluorouracil","mitomycin","durvalumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7517","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7517","title":"Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pomalidomide","carfilzomib","daratumumab"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4205","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4205","title":"Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":["mesothelin"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4521","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4521","title":"Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non–clear cell renal cell carcinoma (nccRCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11508","title":"Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trabectedin","pazopanib","eribulin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3528","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3528","title":"Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS -mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","folfox","folfiri"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16433","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16433","title":"Galeterone and gemcitabine in advanced pancreatic ductal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["pancreatic"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16014","title":"Genetic biomarkers predicting sensitivity to atezolizumab plus bevacizumab in resected hepatocellular carcinoma (HCC): A SNP prediction signature for HCC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2102","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2102","title":"Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","niraparib"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15531","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15531","title":"HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-line treatment in gastrointestinal cancer with liver metastases: A prospective study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","capox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8086","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8086","title":"IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","atezolizumab"],"trials":["imforte"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4117","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4117","title":"Impact of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes in hepatocellular carcinoma treated with atezolizumab–bevacizumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1063","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1063","title":"Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines (TMGs) on ILD/pneumonitis outcomes: A retrospective analysis of patients (pts) treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06 (DB-06).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":["destiny-breast06"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5043","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5043","title":"Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: Extended follow-up.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enzalutamide","talazoparib"],"trials":["talapro-2"],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23340","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23340","title":"Impact of baseline performance status on survival and toxicity with ipilimumab plus nivolumab: A 10-year institutional experience across solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16180","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16180","title":"Impact of GLP-1 receptor agonists on outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter propensity-matched real-world analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4060","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4060","title":"Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ramucirumab","oxaliplatin","paclitaxel"],"trials":[],"targets":["her2"],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16500","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16500","title":"In silico phase III clinical trial of avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma using a machine learning model transfer approach.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sunitinib","avelumab","axitinib"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3683","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3683","title":"INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","folfox"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3579","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3579","title":"Indirect comparison of nivolumab-ipilimumab versus chemotherapy (Chemo) and/or immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) using reconstructed individual patient data (IPD).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5629","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5629","title":"Iparomlimab and tuvonralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer: A phase II umbrella trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["cervical"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.7562","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7562","title":"ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","pomalidomide","isatuximab"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14010","title":"Late line treatment in hormone receptor positive, her 2 neu positive metastatic breast cancer with fulvestrant, abemaciclib, and trastuzumab, including prolonged CNS control.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fulvestrant","abemaciclib","trastuzumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15525","title":"Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15569","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15569","title":"Liposomal irinotecan combined with 5-FU/LV and bevacizumab as second-line therapy for metastatic colorectal cancer: A multicenter, single-arm phase II study (IRIS).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","irinotecan"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9530","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9530","title":"Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3583","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3583","title":"Long-term responders to trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer: Results from the BeTAS real-world study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4585","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4585","title":"Long-term survival update of TRUCE-01: A phase 2 study of preoperative tislelizumab combined with low-dose nab-paclitaxel for muscle-invasive bladder cancer (MIBC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","tislelizumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8502","title":"Lorlatinib vs crizotinib as first-line treatment for advanced ALK + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lorlatinib","crizotinib"],"trials":["crown"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4514","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4514","title":"MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cabozantinib","platinum-etoposide","avelumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11596","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11596","title":"Maintenance pegylated liposomal doxorubicin (PLD) versus active surveillance for advanced soft tissue sarcoma patients who had controlled disease after standard anthracycline-based treatment (MELODY).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pegylated-liposomal-doxorubicin","cytarabine-7-3","doxorubicin"],"trials":[],"targets":[],"cancers":[],"technologies":["active-surveillance"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19574","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19574","title":"Matching-adjusted indirect comparison (MAIC) for belantamab mafodotin (belamaf) with pomalidomide and dexamethasone (BPd) vs daratumumab with pomalidomide and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["belantamab-mafodotin","pomalidomide","daratumumab"],"trials":[],"targets":[],"cancers":["multiple-myeloma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8094","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8094","title":"MC1923: Phase II durvalumab plus lurbinectedin in platinum-resistant relapsed extensive-stage small cell lung cancer after prior chemoimmunotherapy (cohort B).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","durvalumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9521","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9521","title":"Metabolic signatures of response: 2-hydroxybutyric acid as a biomarker in melanoma patients receiving ipilimumab–nivolumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4250","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4250","title":"Multicenter phase Ib/II study of neoadjuvant zolbetuximab plus docetaxel, oxaliplatin, and S-1 (DOS) followed by adjuvant zolbetuximab/S-1 in patients with CLDN18.2-positive resectable gastric or gastroesophageal junction adenocarcinoma (NEOCLAUD).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zolbetuximab","oxaliplatin","docetaxel"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3602","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3602","title":"Multiplexed immunohistochemistry (mIHC) analysis and clinical outcomes of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in patients with refractory colorectal cancer (phase 1b/2).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":["histopathology-ihc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.4099","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4099","title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma: Long-term follow-up of the GERCOR NEONIPIGA phase II study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16131","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16131","title":"Neoadjuvant serplulimab plus nab-paclitaxel and SOX in locally advanced gastric or gastroesophageal junction adenocarcinoma: An interim analysis of a multicenter, randomized, double-blind, phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","serplulimab"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6139","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6139","title":"Neoadjuvant therapy for head and neck squamous cell carcinoma based on hyperprogression genotyping: Cetuximab beta combined with chemotherapy with or without camrelizumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab","cetuximab"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4055","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4055","title":"Nimotuzumab combined with paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma: A prospective, multicenter, double-blind, randomized controlled clinical study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9532","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9532","title":"Nivolumab + relatlimab (NIVO + RELA) in advanced melanoma: 5-year update of RELATIVITY-047.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["relatlimab-nivolumab","nivolumab"],"trials":["relativity-047"],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4549","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4549","title":"Nivolumab and Ipilimumab (NIVO IPI) as first-line (1L) treatment for patients with metastatic renal-cell carcinoma (mRCC): A real-world benchmarking analysis from the International mRCC Database Consortium (IMDC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16167","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16167","title":"Nivolumab and ipilimumab as second or later line therapy in hepatocellular carcinoma: A retrospective study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4006","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4006","title":"Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["her2"],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20630","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20630","title":"Nivolumab plus ipilimumab with chemotherapy as first-line therapy for NSCLC: A single-center real-world experience.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6021","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6021","title":"Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: Results of the phase 2 NAVIGATION study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lenvatinib","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["thyroid"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8625","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8625","title":"Osimertinib combined with bevacizumab and chemotherapy as 1L treatment in EGFR-mutated metastatic non-squamous non-small cell lung cancer (nsq NSCLC) with concurrent mutations.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","osimertinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4575","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4575","title":"Outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC) by NECTIN4 and HER2 RNA expression: Exploratory analyses from JAVELIN Bladder 100.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["platinum-etoposide","avelumab"],"trials":["javelin-bladder-100"],"targets":["her2"],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8091","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8091","title":"Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","durvalumab","paclitaxel"],"trials":[],"targets":[],"cancers":["sclc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18072","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18072","title":"Pathologic response and surgical conversion after preoperative docetaxel, cisplatin, and oral 5-FU with or without PD-1 inhibitors in resectable HNSCC: A retrospective cohort study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["docetaxel","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16066","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16066","title":"Pembrolizumab vs nivolumab plus chemotherapy in metastatic gastric cancer: TriNetX propensity score–matched analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4083","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4083","title":"Perioperative durvalumab plus neoadjuvant chemoradiotherapy (CROSS) with and without tremelimumab in esophageal adenocarcinoma: The prospective phase II RICE trial (NCT04159974).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tremelimumab","durvalumab"],"trials":["cross"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2005","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2005","title":"Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: Final results from the phase 2a step (OLA-TMZ-RTE-01).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","olaparib"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9600","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9600","title":"Phase 1b/2 trial of melphalan-percutaneous hepatic perfusion (PHP) therapy and nivolumab/relatlimab in patients with metastatic melanoma and liver metastasis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["relatlimab-nivolumab","nivolumab","melphalan"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":["percutaneous-hepatic-perfusion"]}},{"doi":"10.1200/jco.2026.44.16_suppl.7002","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7002","title":"Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cytarabine-7-3","epcoritamab","rituximab"],"trials":[],"targets":[],"cancers":["dlbcl"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8665","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8665","title":"Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","carboplatin","pemetrexed"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8671","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8671","title":"Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nogapendekin-alfa","tislelizumab","docetaxel"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.11578","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11578","title":"Phase I trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with TSC1/2 alterations: Preliminary results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9603","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9603","title":"Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA) ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (MM) (TRINITY).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1164","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","title":"Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4243","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4243","title":"Phase II RAINSPOT: A multicentric open label trial of zolbetuximab-paclitaxel-ramucirumab in second-line setting for CLDN18.2-positive gastro-esophageal adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["zolbetuximab","ramucirumab","paclitaxel"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6016","title":"Phase II randomized trial of radiotherapy with pembrolizumab vs. cisplatin for unfavorable-risk p16+ head and neck squamous cell carcinoma (KEYCHAIN).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4637","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4637","title":"Phase II study of cemiplimab ± fianlimab following SBRT for oligometastatic clear-cell RCC (LAG-BOOST).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cemiplimab","fianlimab"],"trials":["fianlimab-phase3-melanoma"],"targets":[],"cancers":[],"technologies":["sbrt"]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14575","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14575","title":"Phase II study of nab-paclitaxel and S-1 combined with tislelizumab as first-line treatment for advanced gallbladder cancer: Preliminary results.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","tislelizumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5560","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5560","title":"Phase II study of sintilimab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2575","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2575","title":"Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1016","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1016","title":"Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["giredestrant","everolimus"],"trials":["evera"],"targets":["estrogen-receptor","her2","cdk4-6"],"cancers":[],"technologies":["cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.11575","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.11575","title":"Preliminary results of pegylated liposomal doxorubicin, dacarbazine, and toripalimab in patients with advanced primary cardiac sarcoma: An interim analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pegylated-liposomal-doxorubicin","toripalimab","doxorubicin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3581","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3581","title":"Propensity score–matched analysis of trifluridine-tipiracil plus bevacizumab (FTD/TPI+Bev) vs anti-EGFR re-treatment in pretreated metastatic colorectal cancer (mCRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":["egfr"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.533","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.533","title":"Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","pyrotinib"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13024","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13024","title":"Pyrotinib versus pertuzumab plus trastuzumab and taxane as first-line therapy for HER2-positive advanced breast cancer: A retrospective cohort study using propensity score overlap weighting.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab","pyrotinib"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6504","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6504","title":"Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3 -mutated AML.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["quizartinib","decitabine-cedazuridine","venetoclax"],"trials":[],"targets":["flt3"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5131","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5131","title":"Randomized phase 1 trial of cisplatin-based chemotherapy with or without sodium thiosulfate for men with metastatic germ cell tumor (GCT).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sodium-thiosulfate","gemcitabine-cisplatin","cisplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2094","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2094","title":"Randomized phase 2 trial of ruxolitinib in combination with radiation and temozolomide compared to radiation and temozolomide for newly diagnosed glioblastoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","ruxolitinib"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8676","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8676","title":"Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound EGFR -mutated non-small cell lung cancer (WJOG17323L: AGEHA study).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["amivantamab","lazertinib","afatinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e18533","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18533","title":"Real-world comparative effectiveness of decitabine/cedazuridine plus venetoclax versus azacitidine plus venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["decitabine-cedazuridine","azacitidine","venetoclax"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9558","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9558","title":"Real-world comparison of ipilimumab–nivolumab dosing strategies in melanoma brain metastases.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16223","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16223","title":"Real-world conversion surgery, survival outcomes, and safety of atezolizumab plus bevacizumab with TACE in unresectable hepatocellular carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3034","title":"Real-world effectiveness of sacituzumab govitecan (SG) versus trastuzumab deruxtecan (T-DXd) in HER2-negative (HER2-) metastatic breast cancer (MBC) in China: A propensity-score–matched study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","sacituzumab-govitecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e24189","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e24189","title":"Real-world feasibility and tolerability of Pedmark for otoprotection in young adults receiving cisplatin for solid tumors.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-cisplatin","cisplatin","sodium-thiosulfate"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1034","title":"Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","sacituzumab-govitecan","trastuzumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9548","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9548","title":"Real-world outcomes of dual checkpoint inhibition (nivolumab + ipilimumab) versus anti-PD-1 monotherapy in metastatic uveal melanoma: Impact of local therapy and adjusted survival analysis—A multicenter retrospective study in Russia.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["pd1"],"cancers":["uveal-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16597","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16597","title":"Real-world outcomes of enfortumab vedotin plus pembrolizumab compared with platinum-based chemotherapy in metastatic urothelial carcinoma in a propensity-matched global analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enfortumab-vedotin","pembrolizumab","platinum-etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16488","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16488","title":"Real-world outcomes of FOLFOX with or without bevacizumab in small bowel and ampullary adenocarcinoma: A propensity-matched analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","folfox"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5574","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5574","title":"Real-world outcomes of olaparib with versus without bevacizumab in bevacizumab-naïve BRCA1/2-mutated ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab","olaparib"],"trials":[],"targets":["brca"],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16546","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16546","title":"Real-world outcomes with nivolumab–ipilimumab in metastatic renal cell carcinoma by nephrectomy status: A single-center study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6034","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6034","title":"Reirradiation with NBTXR3/SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma (HNSCC) in the phase I trial study 1100.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":["sbrt"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5637","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5637","title":"REJOICE-Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["raludotatug-deruxtecan","platinum-etoposide"],"trials":["rejoice-ovarian01"],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e14079","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e14079","title":"Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nogapendekin-alfa","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":["pdl1"],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.10029","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10029","title":"Results of a phase II trial of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-deficient cancers.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16219","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16219","title":"Safety and efficacy of atezolizumab with bevacizumab (A+B) for hepatocellular carcinoma (HCC) in patients with Child-Pugh (CP) class B cirrhosis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["hcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e19040","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e19040","title":"Safety and efficacy of nivolumab combined with brentuximab vedotin in patients with relapsed and refractory classic Hodgkin lymphoma: Systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["brentuximab-vedotin","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["hodgkin-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1055","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1055","title":"Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)–permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","pertuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6046","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6046","title":"Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["carboplatin","paclitaxel","cetuximab"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e13074","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13074","title":"Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: A systematic review and meta-analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","sacituzumab-govitecan","trastuzumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e23552","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23552","title":"Single-institution clinical outcomes with pembrolizumab plus neoadjuvant radiation (SARC032 regimen) with or without neoadjuvant doxorubicin/ifosfamide in high grade soft tissue sarcomas.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","doxorubicin","ifosfamide"],"trials":[],"targets":[],"cancers":["sarcoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20138","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20138","title":"Survival outcomes with first-line platinum–etoposide plus durvalumab versus platinum–etoposide alone in extensive-stage small cell lung cancer with metastatic disease including brain metastases: A real world analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["durvalumab","platinum-etoposide","etoposide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15617","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15617","title":"TACE/HAIC combined with bevacizumab and tislelizumab as third-line therapy for colorectal cancer with unresectable liver metastases: A prospective, observational real-world study (TABTiC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5145","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5145","title":"TALENT: A randomized phase 2 study of talazoparib with or without enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) alterations after progression on abiraterone acetate.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["abiraterone","enzalutamide","talazoparib"],"trials":[],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9562","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9562","title":"The efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma: A prospective, single-center, phase 2 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide","toripalimab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16463","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16463","title":"The TIGeR-PaC phase 3 clinical trial examining intra-arterial gemcitabine versus intravenous gemcitabine: Pharmacokinetic and pharmacodynamic sub-study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2677","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2677","title":"The TIME trial: Phase II randomized controlled trial of time-of-day–specified nivolumab and ipilimumab for advanced melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps8134","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps8134","title":"TIGOS-LS, an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["durvalumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["sclc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21607","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21607","title":"Timing of palliative care referral and overall survival in patients with melanoma brain metastases treated with ipilimumab and nivolumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3530","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3530","title":"Tislelizumab plus cetuximab and irinotecan in relapsed/refractory RAS/BRAF wild-type and microsatellite stable metastatic colorectal cancer: A randomized, controlled, multicenter study (TEC2).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","irinotecan","cetuximab"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15540","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15540","title":"Tislelizumab, bevacizumab, and chemotherapy as second-line therapy in PD-L1-positive, RAS-mutant metastatic colorectal cancer: A single-arm, phase II clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":["pdl1"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8014","title":"Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lurbinectedin","atezolizumab"],"trials":["imforte"],"targets":[],"cancers":["sclc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1012","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1012","title":"Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab","durvalumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16506","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16506","title":"Treatment beyond progression after early radiographic changes on first-line ipilimumab/nivolumab in metastatic clear cell renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8515","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8515","title":"Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 , KEAP1 , and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","tremelimumab","durvalumab"],"trials":[],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9604","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9604","title":"TrioMBM: A multicenter, phase II trial of relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ipilimumab","relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4618","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4618","title":"TRUCE-11: An open-label, single-arm, multicenter phase II study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["gemcitabine-nab-paclitaxel","paclitaxel","tislelizumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2096","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2096","title":"TTFields with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields with maintenance TMZ and placebo for newly diagnosed glioblastoma: The phase 3 EF-41/KEYNOTE D58 trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4144","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4144","title":"Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm): A multicenter retrospective study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["atezolizumab","bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4010","title":"Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","zanidatamab"],"trials":["herizon-gea-01"],"targets":["pdl1","her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8570","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8570","title":"1L olomorasib plus pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","olomorasib"],"trials":[],"targets":["kras"],"cancers":[],"technologies":["kras-inhibitors"]}},{"doi":"10.1200/jco.2026.44.16_suppl.9518","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9518","title":"A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":["pd1"],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3588","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3588","title":"A four-marker-protein signature to predict ramucirumab efficacy in combination with TAS-102 in advanced colorectal cancer: Translational analysis of the RAMTAS trial of the German AIO (AIO-KRK-0316/IKF643).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ramucirumab","trifluridine-tipiracil"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2010","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2010","title":"A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): Updated efficacy and safety.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["vorasidenib"],"trials":["indigo"],"targets":["idh"],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16607","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16607","title":"A kidney-sparing approach using disitamab vedotin plus toripalimab for high-risk upper urinary tract urothelial carcinoma in patients with impaired renal function: Preliminary results from a phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["disitamab-vedotin","toripalimab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16619","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16619","title":"A matched-adjusted indirect comparison (MAIC) of nogapendekin alfa inbakicept-pmln plus bacillus Calmette–Guérin (NAI+BCG) and pembrolizumab in patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary disease.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nogapendekin-alfa","pembrolizumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps653","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps653","title":"A molecular subtype–guided, chemotherapy-free neoadjuvant strategy using SHR-A1811 plus pertuzumab for hormone receptor–positive/HER2-positive breast cancer: A phase II trial in progress.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pertuzumab","trastuzumab-rezetecan"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20748","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20748","title":"A multicenter pilot study of afatinib re-challenge in patients with EGFR -mutated non-squamous non–small cell lung cancer previously treated with osimertinib.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["osimertinib","afatinib"],"trials":[],"targets":["egfr"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4630","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4630","title":"A multicenter randomized controlled clinical study of neoadjuvant combination of axitinib plus toripalimab to improve disease-free survival of patients with renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["toripalimab","axitinib"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3598","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3598","title":"A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer: Updated results from the CAPCET study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cetuximab","folfox"],"trials":[],"targets":["braf"],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2001","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2001","title":"A multicenter randomized phase III study for newly diagnosed, maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide versus chemoradiotherapy alone: Japan Clinical Oncology Group study JCOG1703 (MACS study).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3546","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3546","title":"A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with Neo RAS wild-type metastatic colorectal cancer (C-PROWESS trial).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["panitumumab","irinotecan"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4176","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4176","title":"A multicenter single-arm study of induction EC/EP plus camrelizumab followed by maintenance camrelizumab plus apatinib in treatment-naive advanced or metastatic extrapulmonary neuroendocrine carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["camrelizumab-rivoceranib","camrelizumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15150","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15150","title":"A novel bispecific RDC+ADC theranostic approach to overcome trastuzumab deruxtecan resistance and tumor heterogeneity.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e15640","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e15640","title":"A novel regimen of liposomal irinotecan plus capecitabine as total neoadjuvant therapy for locally advanced rectal cancer (LipCap): A phase II trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","irinotecan"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2065","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2065","title":"A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂ combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4500","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4500","title":"A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["radium-223","cabozantinib"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6012","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6012","title":"A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["darolutamide","goserelin"],"trials":[],"targets":["androgen-receptor"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9502","title":"A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps9613","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps9613","title":"A phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["basal-cell-carcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8567","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8567","title":"A phase 2 study of plinabulin (Plin)/docetaxel (Doc) plus pembrolizumab (Pemb) in metastatic NSCLC (mNSCLC) after acquired resistance (AR) to anti–PD-1/L1 alone or in chemotherapy combination: Efficacy and immunophenotyping.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","docetaxel"],"trials":[],"targets":["pd1"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9519","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9519","title":"A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["relatlimab-nivolumab","nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps2104","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2104","title":"A phase 3 randomized trial comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 diffuse gliomas in adults.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5139","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5139","title":"A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pasritamig","docetaxel"],"trials":[],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9525","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9525","title":"A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ 212 Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16065","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16065","title":"A phase Ib/II clinical study of adebrelimab in combination with capecitabine and oxaliplatin for previously untreated patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","oxaliplatin"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5575","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5575","title":"A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps3677","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps3677","title":"A phase II exploratory study of iparomlimab and tuvonralimab (QL1706) combined with bevacizumab in patients with locally advanced or metastatic MSI-H/dMMR colorectal cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["bevacizumab-glioma","bevacizumab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6123","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6123","title":"A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","pemetrexed"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16261","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16261","title":"A phase II trial evaluating liposomal irinotecan combined with capecitabine as second-line therapy for biliary tract cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","irinotecan"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4219","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4219","title":"A phase II trial of binimetinib in combination with encorafenib in patients with pancreatic malignancies and a somatic BRAF V600E mutation.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["binimetinib","encorafenib"],"trials":[],"targets":["braf"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3552","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3552","title":"A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["fruquintinib","cadonilimab"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5615","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5615","title":"A phase II trial of lenvatinib plus pembrolizumab in patients (pts) with endometrial or ovarian carcinosarcoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","lenvatinib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4629","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4629","title":"A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.9553","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9553","title":"A phase II trial of olaparib in combination with pembrolizumab in metastatic uveal melanoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","olaparib"],"trials":[],"targets":[],"cancers":["uveal-melanoma","melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6502","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6502","title":"A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tagraxofusp","venetoclax"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4258","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4258","title":"A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trifluridine-tipiracil","oxaliplatin"],"trials":[],"targets":[],"cancers":["cholangiocarcinoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4641","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4641","title":"A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","pembrolizumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps11202","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps11202","title":"A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":["histopathology-ihc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.6511","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6511","title":"A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["azacitidine","venetoclax"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4501","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4501","title":"A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cadonilimab","axitinib"],"trials":[],"targets":[],"cancers":["rcc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5057","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5057","title":"A randomized phase Ib/II study of enzalutamide (Enza) with and without ribociclib (Rib) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that retains RB expression: RiboX study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["enzalutamide","ribociclib"],"trials":[],"targets":[],"cancers":["prostate"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.3534","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3534","title":"A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","fruquintinib"],"trials":[],"targets":[],"cancers":["colorectal"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5506","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5506","title":"A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mirvetuximab-soravtansine","platinum-etoposide"],"trials":[],"targets":["folr1"],"cancers":["ovarian"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps6135","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps6135","title":"A randomized, non-comparative, multicenter phase II trial of neoadjuvant becotatug vedotin alone or combined with immune checkpoint inhibitors (penpulimab/ivonescimab) in resectable locally advanced head and neck squamous cell carcinoma.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ivonescimab","penpulimab"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":["checkpoint-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.7062","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7062","title":"A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["acalabrutinib","zanubrutinib"],"trials":[],"targets":[],"cancers":["mantle-cell-lymphoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e21515","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e21515","title":"A retrospective analysis of patients with metastatic melanoma treated with sequential metronomic temozolomide after immune therapy failure.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":["melanoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps5633","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps5633","title":"A single-arm, phase 2 study of neoadjuvant mirvetuximab soravtansine and carboplatin for FRα-expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (M25-231; NCT06890338; GOG-3115).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["mirvetuximab-soravtansine","carboplatin"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4246","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4246","title":"A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2-negative gastroesophageal adenocarcinomas.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["ivonescimab","folfox"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1539","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1539","title":"Access to trastuzumab deruxtecan for HER2-low metastatic breast cancer in Brazil’s Unified Public Health System: A population-impact model.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1106","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1106","title":"ADAPT-T-DXd: Multi-institutional real-world study of dose-adapted trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps1154","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1154","title":"ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2− advanced breast cancer (aBC) patients with ESR1 -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["elacestrant","everolimus"],"trials":[],"targets":["her2","cdk4-6"],"cancers":[],"technologies":["endocrine-therapy","cdk46-inhibitor"]}},{"doi":"10.1200/jco.2026.44.16_suppl.535","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.535","title":"Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":[],"trials":["destiny-breast05","katherine"],"targets":["her2"],"cancers":[],"technologies":["adc"]}},{"doi":"10.1200/jco.2026.44.16_suppl.508","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.508","title":"Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): A phase II clinical trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["capecitabine-temozolomide","trastuzumab"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e16275","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16275","title":"Adjuvant durvalumab or tislelizumab combined with S-1 for resected high-risk biliary tract cancers in China: A multicenter, two-cohort, single-arm, open-label, phase 2 trial preliminary analysis.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["tislelizumab","durvalumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6092","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6092","title":"Adjuvant nivolumab in addition to postoperative radiation therapy in locally advanced head and neck cancer: Results of the phase II NadiHN trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4606","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4606","title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Real-world evidence from the SOGUG-NIADY study of the Spanish Oncology Genitourinary Group (SOGUG).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps4249","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps4249","title":"Adjuvant oxaliplatin plus S-1 versus docetaxel plus S-1 for stage III gastric cancer after D2 gastrectomy (DRAGON-Adjuvant): A multicenter, open-label, phase 3, randomized, non-inferiority study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["oxaliplatin","docetaxel"],"trials":[],"targets":[],"cancers":["gastric"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e12503","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12503","title":"Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab","pertuzumab"],"trials":[],"targets":["her2"],"cancers":["breast-her2-positive"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8605","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8605","title":"Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["osimertinib","afatinib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e20520","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e20520","title":"AI-powered volumetric and radiomic MRI brain analysis for prognostication and treatment response patterns in ALK+ NSCLC brain metastases: Comparative outcomes of brigatinib versus crizotinib.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["crizotinib","brigatinib"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.8503","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8503","title":"ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK + NSCLC.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["neladalkib"],"trials":["alkove-1"],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.6026","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6026","title":"An open-label, randomized phase 2 trial of ramucirumab and pembrolizumab versus pembrolizumab as first-line therapy for PD-L1–positive, recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","ramucirumab"],"trials":[],"targets":["pdl1"],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2577","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2577","title":"Analysis of circulating small extracellular vesicle-associated miRNA in head and neck squamous cell carcinoma (HNSCC): Biomarker discovery in pre-operative neoadjuvant nivolumab.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["nivolumab","relatlimab-nivolumab"],"trials":[],"targets":[],"cancers":["head-and-neck"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e12647","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12647","title":"Anthracycline- and immunotherapy-free neoadjuvant chemotherapy versus KEYNOTE-522 regimen in early-stage triple-negative breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["cytarabine-7-3"],"trials":["keynote-522"],"targets":[],"cancers":["tnbc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1014","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1014","title":"ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan"],"trials":["ascent-03"],"targets":[],"cancers":["tnbc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.tps644","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps644","title":"ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","atezolizumab"],"trials":[],"targets":[],"cancers":["tnbc"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.1030","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1030","title":"Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["trastuzumab-deruxtecan","trastuzumab"],"trials":[],"targets":["her2"],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e17613","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e17613","title":"Association of omentectomy with reduced therapeutic efficacy of lenvatinib plus pembrolizumab in patients with endometrial cancer.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["pembrolizumab","lenvatinib"],"trials":[],"targets":[],"cancers":["endometrial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.4568","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.4568","title":"Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["sacituzumab-govitecan","avelumab"],"trials":[],"targets":[],"cancers":["urothelial"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.e22002","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e22002","title":"Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["lisocabtagene-maraleucel","axicabtagene-ciloleucel"],"trials":[],"targets":[],"cancers":[],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.2015","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.2015","title":"Azeliragon, a RAGE inhibitor, plus temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Final results from a dose-finding phase in the CAN-201 NDG trial.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["temozolomide","capecitabine-temozolomide"],"trials":[],"targets":[],"cancers":["glioblastoma"],"technologies":[]}},{"doi":"10.1200/jco.2026.44.16_suppl.5529","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5529","title":"Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.","issue":"16_suppl","date":"2026-06-01","lba":false,"refs":{"drugs":["paclitaxel","platinum-etoposide"],"trials":[],"targets":[],"cancers":["ovarian"],"technologies":[]}}],"errors":[]}